Capital Fund Management S.A. Raises Holdings in Hologic, Inc. (NASDAQ:HOLX)

Capital Fund Management S.A. increased its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 77.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 158,376 shares of the medical equipment provider's stock after acquiring an additional 69,187 shares during the quarter. Capital Fund Management S.A. owned about 0.07% of Hologic worth $11,417,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Brooklyn Investment Group lifted its stake in shares of Hologic by 14.7% during the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after buying an additional 145 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC boosted its holdings in shares of Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock worth $602,000 after acquiring an additional 169 shares during the period. UMB Bank n.a. lifted its holdings in Hologic by 4.1% during the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock worth $343,000 after purchasing an additional 188 shares in the last quarter. Finally, Capital Investment Counsel Inc grew its holdings in Hologic by 3.6% during the 4th quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock valued at $413,000 after buying an additional 200 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Up 1.1 %

Shares of HOLX stock traded up $0.62 during midday trading on Thursday, reaching $57.12. 1,245,949 shares of the stock were exchanged, compared to its average volume of 1,927,121. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 1 year low of $56.00 and a 1 year high of $84.67. The firm has a market cap of $12.82 billion, a PE ratio of 18.00, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82. The company's 50 day moving average is $61.87 and its two-hundred day moving average is $71.15.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on HOLX shares. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Leerink Partners lowered Hologic from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Raymond James reaffirmed an "outperform" rating and issued a $90.00 price target (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Stephens reissued an "overweight" rating and issued a $84.00 price target on shares of Hologic in a research note on Thursday, February 6th. Finally, Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.